News for MGEN Stock

miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc. miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL) miRagen Announces Leadership Transition and Review of Strategic Alternatives  miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates miRagen Regains Compliance With Nasdaq Listing Requirements miRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating Officer miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference miRagen to Report Second Quarter 2020 Financial Results on August 5, 2020 miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma